Burshtein Joshua, Shah Milaan, Zakria Danny, Dinehart Scott, Lewin Jesse, Monks George, Mortazie Michael, Trotter Shannon, Schlesinger Todd, Lebwohl Mark, Rigel Darrell
J Drugs Dermatol. 2025 May 1;24(5):465-471. doi: 10.36849/JDD.8827.
Hedgehog inhibitors (HHIs) can be used to treat patients with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation or whose tumors have recurred following radiation or surgery. The purpose of this expert consensus panel is to guide HHI usage, thereby informing clinical decision-making and optimizing patient care.
A comprehensive literature search was completed on May 1, 2024, using the keywords "basal cell carcinoma," "hedgehog inhibitor," "sonidegib," and "vismodegib". A panel of eight dermatologists with significant expertise in the treatment of BCC gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned.
The literature search produced 200 articles. A screening of the studies resulted in 19 articles that met the criteria. The panel unanimously voted to adopt 8 consensus statements and recommendations, two were given a strength of "A", three were given a strength of "B", and three were given a strength of "C".
Sonidegib and vismodegib are FDA-approved HHIs that can decrease the size of laBCC tumors prior to surgical intervention or be used as primary therapy in certain circumstances. The most common adverse events include muscle spasms, alopecia, and taste alterations.
Burshtein J, Shah M, Zakria D, et al. Efficacy and safety of hedgehog inhibitors for advanced basal cell carcinoma: an expert consensus panel. J Drugs Dermatol. 2025;24(5):465-471. doi:10.36849/JDD.8827.
刺猬信号通路抑制剂（HHIs）可用于治疗局部晚期基底细胞癌（laBCC）患者，这些患者不适合手术或放疗，或其肿瘤在放疗或手术后复发。本专家共识小组的目的是指导HHIs的使用，从而为临床决策提供依据并优化患者护理。
于2024年5月1日完成了一项全面的文献检索，使用的关键词为“基底细胞癌”“刺猬信号通路抑制剂”“索尼德吉”和“维莫德吉”。由八位在BCC治疗方面具有丰富专业知识的皮肤科医生组成的小组聚集在一起，对文章进行审查并制定共识声明。采用改良的德尔菲法批准每条声明，并给出推荐强度。
文献检索共得到200篇文章。对这些研究进行筛选后，有19篇文章符合标准。该小组一致投票通过了8条共识声明和建议，其中两条的推荐强度为“A”，三条为“B”，三条为“C”。
索尼德吉和维莫德吉是美国食品药品监督管理局（FDA）批准的HHIs，可在手术干预前缩小laBCC肿瘤的大小，或在某些情况下用作一线治疗。最常见的不良事件包括肌肉痉挛、脱发和味觉改变。
Burshtein J, Shah M, Zakria D,等。刺猬信号通路抑制剂治疗晚期基底细胞癌的疗效和安全性：专家共识小组。《药物皮肤病学杂志》。2025；24（5）：465 - 471。doi:10.36849/JDD.8827
